Govt expands committee for drug and medical device pricing reforms, includes more industry representation
The government has expanded a committee to include more industry representation for reviewing drug and medical device pricing reforms. This move aims to ensure better availability of medicines and devices, while also providing incentives for industry growth and export sustainability. The committee will engage with industry experts and associations to evaluate pricing and availability issues. Ultimately, the government will make the final decisions, with the committee focusing on balancing pricing and availability of essential medicines and designing a price moderation framework for medical devices.